
# GO WITH A HYALURONIC ACID DESIGNED FOR PERFORMANCE<sup>1,2</sup>

Give them EUFLEXXA for improved function and long-lasting pain relief<sup>3\*</sup>

### Powerful OA knee pain reductions<sup>3</sup>

In a 12-week pivotal trial, maximum pain relief was achieved with EUFLEXXA 10 weeks after the 3rd injection^{1.21}



Pain reduction began as early as 1 week post-injection and improved with each injection: 19% after injection 1 (n=160), 37% after injection 2 (n=159), and 48% after injection 3 (n=159).<sup>2†</sup>

The most common adverse events were arthralgia (11/160), back pain (1/160), blood pressure increase (3/160), joint effusion (1/160), joint swelling (3/160), nausea (1/160), paresthesia (2/160), feeling of sickness of injection (3/160), skin irritation (1/160), and tenderness in study knee (1/160).<sup>1</sup>

\*For up to 26 weeks in a controlled study assessing the safety and efficacy of EUFLEXXA vs saline. Primary efficacy outcome was based on the 50-foot walk test.<sup>3</sup> <sup>1</sup>In a multicenter, prospective, randomized, controlled, double-blind, 12-week, pivotal clinical trial in patients with confirmed OA of the knee (N=321), the primary endpoint was non-inferiority in safety and effectiveness between EUFLEXXA (n=157) and Synvisc (n=158). Efficacy was measured by mean change from baseline in 5 WOMAC pain scores (VAS [100-mm scale] and index analysis). Synvisc reduced OA knee pain by 55% (*P*<0.0001).<sup>12</sup>

prescribed

HA=hyaluronic acid; OA=osteoarthritis; VAS=visual analog scale; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index.

### INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

### IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

Please see additional Important Safety Information on back and Full Prescribing Information in pocket.




HA in patient access<sup>5</sup>

Simplified access with preferred

status for EUFLEXXA on many plans

## TREATMENT THAT PERFORMS AND CAN BE REPEATED<sup>1,3,6</sup>



FLEXX trial primary efficacy outcome demonstrated EUFLEXXA was superior to saline in reducing OA knee pain at 26 weeks. Median percent reduction from baseline: EUFLEXXA 53% vs saline 38%.<sup>3</sup>

In a continuation of the FLEXX trial (N=588), the open-label extension study of the FLEXX trial (N=219) showed that repeat treatment with EUFLEXXA was safe for an additional 26 weeks.<sup>6</sup>

Open-label extension study was not designed to establish long-term efficacy of a repeat injection series of EUFLEXXA.

In the FLEXX trial, the most common treatment-related adverse events were arthralgia (27/293), back pain (12/293), and musculoskeletal pain (6/293). In the FLEXX extension, the most common treatment-related adverse events were arthralgia (19/219), joint swelling (6/219), and back pain (6/219).<sup>16</sup>

\*Only data points from EUFLEXXA patients are shown.

### Give your patients the performance they're looking for. To learn more about EUFLEXXA, ask your EUFLEXXA representative or visit hcp.euflexxa.com

#### **IMPORTANT SAFETY INFORMATION (continued)**

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

#### Please see Full Prescribing Information in pocket.

REFERENCES: 1. EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. *Osteoarthritis Cartilage*. 2006;14(2):154-162. **3.** Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). *Semin Arthritis Rheum*. 2009;39(1):1-9. **4.** Rolling 12-month average of IQVIA claims data based on unique patients (August 2018-August 2019). **5.** MMIT medical benefit data (October 2019); preferred status for commercial, Medicare Advantage, and managed Medicaid plans. **6.** Altman RD, Rosen JE, Bloch DA, et al. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. *Osteoarthritis Cartilage*. 2011;19(10):1169-1175.



EUFLEXXA® is a registered trademark of Ferring B.V. ©2019 Ferring B.V. All rights reserved. 11/19 US-EU-1900026

